NO314979B1 - Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse - Google Patents
Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse Download PDFInfo
- Publication number
- NO314979B1 NO314979B1 NO19965191A NO965191A NO314979B1 NO 314979 B1 NO314979 B1 NO 314979B1 NO 19965191 A NO19965191 A NO 19965191A NO 965191 A NO965191 A NO 965191A NO 314979 B1 NO314979 B1 NO 314979B1
- Authority
- NO
- Norway
- Prior art keywords
- bismuth
- preparation
- administered
- treatment
- per day
- Prior art date
Links
- 229910052797 bismuth Inorganic materials 0.000 title claims abstract description 52
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 208000025609 Urogenital disease Diseases 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 24
- 230000003071 parasitic effect Effects 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 7
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims description 6
- 229960000782 bismuth subsalicylate Drugs 0.000 claims description 6
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims description 4
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 claims description 4
- 229960000199 bismuth subgallate Drugs 0.000 claims description 4
- SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 claims description 4
- 229940104825 bismuth aluminate Drugs 0.000 claims description 3
- 229960004645 bismuth subcitrate Drugs 0.000 claims description 3
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 claims description 3
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 claims description 2
- 241001126846 Encephalitozoon hellem Species 0.000 claims description 2
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 claims description 2
- 229940036358 bismuth subcarbonate Drugs 0.000 claims description 2
- 229940120293 vaginal suppository Drugs 0.000 claims description 2
- 239000006216 vaginal suppository Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 3
- 239000004599 antimicrobial Substances 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 9
- 150000001621 bismuth Chemical class 0.000 description 6
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 3
- 229960003159 atovaquone Drugs 0.000 description 3
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 3
- 229960001482 bismuth subnitrate Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 239000002496 intravaginal dosage form Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940059082 douche Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000243234 Encephalitozoon Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 241001126829 Nosema Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001492488 Pleistophora Species 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- -1 araoxicillin Chemical compound 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940101070 pepto-bismol Drugs 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- SPRBJFWIUVWXBT-UHFFFAOYSA-K tripotassium 2-hydroxypropane-1,2,3-tricarboxylate 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SPRBJFWIUVWXBT-UHFFFAOYSA-K 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56885295A | 1995-12-07 | 1995-12-07 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965191D0 NO965191D0 (no) | 1996-12-05 |
| NO965191L NO965191L (no) | 1997-06-09 |
| NO314979B1 true NO314979B1 (no) | 2003-06-23 |
Family
ID=24273004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19965191A NO314979B1 (no) | 1995-12-07 | 1996-12-05 | Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5882686A (pt) |
| EP (1) | EP0776665B1 (pt) |
| AT (1) | ATE232736T1 (pt) |
| DE (1) | DE69626260T2 (pt) |
| DK (1) | DK0776665T3 (pt) |
| ES (1) | ES2192219T3 (pt) |
| NO (1) | NO314979B1 (pt) |
| PT (1) | PT776665E (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2767699A1 (fr) | 1997-08-28 | 1999-02-26 | Oreal | Composition filmogene epaissie |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR962163A (pt) * | 1950-06-02 | |||
| US4049817A (en) * | 1972-08-14 | 1977-09-20 | Sandoz Ltd. | Synergistic compositions |
| US4514421A (en) * | 1979-08-30 | 1985-04-30 | Herschler R J | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it |
| US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
| JPS63174926A (ja) * | 1987-01-09 | 1988-07-19 | Nitto Kasei Kk | 家禽用抗コクシジウム剤 |
| US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
| KR100193933B1 (ko) * | 1990-07-20 | 1999-06-15 | 에밀리오 캠포레시, 존 페르구손 | 비스무트와 폴리아크릴레이트와의 수용성 착체, 이의 제조 방법 및 상기 착체 또는 다른 비스무트염을 함유하는 궤양성 대장염 치료용 약제학적 조성물 |
| AUPM596894A0 (en) * | 1994-05-30 | 1994-06-23 | Hybrid Scientific Pty Ltd | Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders |
-
1996
- 1996-12-05 PT PT96308853T patent/PT776665E/pt unknown
- 1996-12-05 DE DE69626260T patent/DE69626260T2/de not_active Expired - Fee Related
- 1996-12-05 AT AT96308853T patent/ATE232736T1/de not_active IP Right Cessation
- 1996-12-05 NO NO19965191A patent/NO314979B1/no unknown
- 1996-12-05 DK DK96308853T patent/DK0776665T3/da active
- 1996-12-05 EP EP96308853A patent/EP0776665B1/en not_active Expired - Lifetime
- 1996-12-05 ES ES96308853T patent/ES2192219T3/es not_active Expired - Lifetime
-
1997
- 1997-09-04 US US08/923,831 patent/US5882686A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2192219T3 (es) | 2003-10-01 |
| EP0776665A1 (en) | 1997-06-04 |
| DE69626260D1 (de) | 2003-03-27 |
| NO965191L (no) | 1997-06-09 |
| ATE232736T1 (de) | 2003-03-15 |
| NO965191D0 (no) | 1996-12-05 |
| DK0776665T3 (da) | 2003-03-31 |
| PT776665E (pt) | 2003-06-30 |
| DE69626260T2 (de) | 2003-12-04 |
| US5882686A (en) | 1999-03-16 |
| EP0776665B1 (en) | 2003-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Soper et al. | Prevention of vaginal trichomoniasis by compliant use of the female condom | |
| Ishibashi et al. | Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis | |
| Lister et al. | Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men | |
| Caselli et al. | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication ofHelicobacter pylori | |
| Mauck et al. | A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II | |
| Vicentini et al. | Gonorrhea, a current disease with ancient roots: from the remedies of the past to future perspectives | |
| Swindell et al. | Audits of antibiotic prescribing in a Bristol hospital. | |
| EP0772445B1 (en) | Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients | |
| Ballagh et al. | Safety of single daily use for one week of C31G HEC gel in women | |
| Young et al. | The Treatment of Infections and Infectious Diseases with Mercurochrome-220 Soluble: An Analysis of Two Hundred and Ten Cases that Furnish Many Definite Examples of a Therapia Sterilisans Magna | |
| NO314979B1 (no) | Anvendelse av vismut for fremstilling av et preparat for behandling eller forebygging av en urogenital lidelse | |
| JPS62161726A (ja) | 胃腸障害の治療及び予防のためのニトロフラントインの使用 | |
| US5827543A (en) | Methods and compositions for the prevention and treatment of urogenital disorders | |
| KR101100713B1 (ko) | 아스코르브산을 포함하는 진균성 중복감염들 및 진균성재발들의 치료용 약학적 조성물들 | |
| Worm et al. | Azithromycin levels in cervical mucus and plasma after a single 1.0 g oral dose for chlamydial cervicitis. | |
| Theodore | Use of sodium propionate in external infections of the eyes | |
| JP2023528884A (ja) | 疾患の処置用の２－（ジエチルアミノ）エチル２－（４－イソブチルフェニル）プロピオネートの局所投与 | |
| Antonelli et al. | A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis | |
| Ladipo et al. | A new vaginal antimicrobial contraceptive formulation: phase I clinical pilot studies | |
| Sholten et al. | Parasitism in an Ontario mental institution: preliminary report. | |
| Edwards et al. | The side-effects of antipsychotic drugs. II. Effects on other physiological systems | |
| Senft et al. | Epidemiology, pathology and clinical features of genital mycoses–1981 status | |
| AL-Khikani | Refractory Fungal Vaginitis Treated By Topical Amphotericin B. Review | |
| KOLMER | Bismuth arsphenamine sulphonate (bismarsen) in the treatment of syphilis and of other spirochetic infections | |
| PERL et al. | Further studies in treatment of female and male trichomoniasis with metronidazole |